GI Cancers | Clinical

March 05, 2021

In an interview with Targeted Oncology, Markus Moehler, MD, PhD, reviewed the potentially practice-changing data from the phase 3 CheckMate 649 clinical trial.

March 02, 2021

Markus Moehler, MD, PhD, discusses the survival outcomes of nivolumab in combination with chemotherapy in patients with advanced gastric cancer.

March 01, 2021

A New Drug Application was submitted to the FDA for ivosidenib tablets as a potential treatment option for patients with previously treated IDH1-mutated cholangiocarcinoma. The company is requesting Priority Review be granted to the application.

February 22, 2021

Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.

February 19, 2021

Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib plus imatinib as treatment of patients with untreated advanced gastrointestinal stromal tumors.

February 15, 2021

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

February 12, 2021

In the phase 2 FIDES-01 clinical trial, treatment with the FGFR inhibitor, derazantinib, led to an objective response rate of 24% in patients with FGFR2 gene fusion-positive advanced intrahepatic cholangiocarcinoma.

February 03, 2021

This past year, 2020, will go down as a practice-changing one for the treatment of esophageal cancer, said Yelena Y. Janjigian, MD.

February 02, 2021

In the phase 1 clinical trial of NBTXR3 with chemotherapy and radiation therapy as treatment of patients with esophageal cancer, the first patient has been dosed with the investigational tumor-agnostic radioenhancer.

January 20, 2021

The FDA has granted a Priority Review to the combination of nivolumab with fluoropyrimidine- and platinum-containing chemotherapy, which is a potential treatment option for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.